Compare AJANTA PHARMA with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA CADILA HEALTHCARE AJANTA PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 28.5 33.9 83.9% View Chart
P/BV x 7.9 6.0 132.9% View Chart
Dividend Yield % 0.4 0.6 76.8%  

Financials

 AJANTA PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
CADILA HEALTHCARE
Mar-20
AJANTA PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,422352 403.6%   
Low Rs898207 434.7%   
Sales per share (Unadj.) Rs233.5139.2 167.7%  
Earnings per share (Unadj.) Rs44.011.8 373.7%  
Cash flow per share (Unadj.) Rs52.218.6 280.9%  
Dividends per share (Unadj.) Rs9.003.50 257.1%  
Dividend yield (eoy) %0.81.3 61.9%  
Book value per share (Unadj.) Rs255.1101.4 251.7%  
Shares outstanding (eoy) m88.021,023.74 8.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.02.0 247.5%   
Avg P/E ratio x26.423.7 111.1%  
P/CF ratio (eoy) x22.215.0 147.8%  
Price / Book Value ratio x4.52.8 164.9%  
Dividend payout %20.529.8 68.8%   
Avg Mkt Cap Rs m102,081286,033 35.7%   
No. of employees `0006.813.4 50.7%   
Total wages/salary Rs m4,30724,145 17.8%   
Avg. sales/employee Rs Th3,022.610,632.7 28.4%   
Avg. wages/employee Rs Th633.41,801.2 35.2%   
Avg. net profit/employee Rs Th569.1898.5 63.3%   
INCOME DATA
Net Sales Rs m20,554142,531 14.4%  
Other income Rs m2111,139 18.5%   
Total revenues Rs m20,765143,670 14.5%   
Gross profit Rs m5,66424,198 23.4%  
Depreciation Rs m7216,965 10.3%   
Interest Rs m123,418 0.3%   
Profit before tax Rs m5,14314,954 34.4%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2733,198 39.8%   
Profit after tax Rs m3,87012,044 32.1%  
Gross profit margin %27.617.0 162.3%  
Effective tax rate %24.821.4 115.7%   
Net profit margin %18.88.5 222.8%  
BALANCE SHEET DATA
Current assets Rs m11,81287,154 13.6%   
Current liabilities Rs m3,77682,694 4.6%   
Net working cap to sales %39.13.1 1,249.5%  
Current ratio x3.11.1 296.8%  
Inventory Days Days7771 108.3%  
Debtors Days Days8294 87.0%  
Net fixed assets Rs m14,398133,236 10.8%   
Share capital Rs m1751,024 17.1%   
"Free" reserves Rs m22,277102,733 21.7%   
Net worth Rs m22,452103,757 21.6%   
Long term debt Rs m732,146 0.0%   
Total assets Rs m26,962236,866 11.4%  
Interest coverage x444.35.4 8,266.6%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x0.80.6 126.7%   
Return on assets %14.46.5 220.5%  
Return on equity %17.211.6 148.5%  
Return on capital %23.013.7 167.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68252,752 20.2%   
Fx outflow Rs m2,10214,504 14.5%   
Net fx Rs m8,58038,248 22.4%   
CASH FLOW
From Operations Rs m3,74825,054 15.0%  
From Investments Rs m-2,228-10,123 22.0%  
From Financial Activity Rs m-1,475-10,942 13.5%  
Net Cashflow Rs m453,989 1.1%  

Share Holding

Indian Promoters % 73.8 74.8 98.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 8.3 18.7%  
FIIs % 7.6 5.9 128.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 11.0 154.5%  
Shareholders   20,968 44,069 47.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   AUROBINDO PHARMA  ORCHID PHARMA  SANOFI INDIA  FULFORD INDIA  SHASUN PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS